This week’s funding activity underscores how MedTech innovation is expanding beyond devices alone, with investors backing integrated platforms spanning therapeutics, diagnostics, biomaterials, and intelligent sensing.
Senseonics announces $80M public offering
Senseonics announced that it commenced an underwritten public offering to sell $80 million in common stock. The offering includes common stock and, for certain investors, pre-funded warrants to purchase common stock.
The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total number of shares included in the public offering.
President and CEO Tim Goodnow
Last week’s tracker: Aidoc, Cofoe & more
Sedivention advances obesity therapy with €2.9M funding
The seed funding round led by bmp Ventures alongside the IBG funds. Additional investors include the strategic investment arm of a global medtech company, High-Tech Gründerfonds (HTGF), superangels, and Cambridge Ventures.
With the new funding, Sedivention plans to advance product development, generate initial clinical data through a first-in-human study, and prepare for subsequent regulatory and market entry steps.
Founder and CMO Ute Nollert
MedVital raises $1.9M in growth funding
The funding round was led by Alkemi Growth Capital, with participation from Sanjay Arora and Shubhan Ventures, along with existing investors. The company had earlier secured funding from 4point0 Health Ventures and several angel investors.
The company said the fresh capital will be utilized to expand its operations, accelerate product development, and strengthen capabilities across medical devices, biomaterials, and biologics.
Co-Founder Varun Gupta
Brighter Signals raises €1.6M for smart sensors
The funding round included backing from Wake Up Capital and ELOKON Ventures, along with regional innovation funding and a Eurostars grant co-funded by the Dutch Enterprise Agency.
The newly raised capital will be used to expand product development and improve the company’s software and data interpretation systems, which convert sensor data into usable inputs for vehicle and robotic systems.
Founder and CEO Andrew Klein
Apollo investment supports vVARDIS’s global Curodont expansion
The investment will support the company’s next phase of global growth and commercial expansion, including the continued rollout of its Curodont product line.
According to vVARDIS, the transaction gives the privately owned medical technology company a valuation of more than $1.0B.
Founders and CEOs Dr. Haley Abivardi and Dr. Goly Abivardi
4D Path announces strategic financing
The company announced the first close of a strategic financing round alongside the appointment of two seasoned healthcare executives to its board of directors.
The financing will accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with biopharma companies.
CEO Jacopo Leonardi
